{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T04:05:56Z","timestamp":1791864356757,"version":"4.3.4"},"reference-count":37,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,17]],"date-time":"2022-11-17T00:00:00Z","timestamp":1668643200000},"content-version":"vor","delay-in-days":1691,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["amjtransplant.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Transplantation"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1111\/ajt.14504","type":"journal-article","created":{"date-parts":[[2017,9,19]],"date-time":"2017-09-19T06:06:35Z","timestamp":1505801195000},"page":"907-915","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":127,"title":["Lower tacrolimus exposure and time in therapeutic range increase the risk of de novo donor-specific antibodies in the first year of kidney transplantation"],"prefix":"10.1016","volume":"18","author":[{"given":"Scott","family":"Davis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane","family":"Gralla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Klem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suhong","family":"Tong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gina","family":"Wedermyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Freed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Wiseman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James E.","family":"Cooper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1111\/ajt.14504_bib1","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1111\/j.1600-6143.2011.03647.x","article-title":"Early ultrastructural changes in renal allografts: correlation with antibody-mediated rejection and transplant glomerulopathy","volume":"11","author":"Haas","year":"2011","journal-title":"Am J Transplant."},{"issue":"4","key":"10.1111\/ajt.14504_bib2","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1097\/TP.0000000000000908","article-title":"Peritubular capillary basement membrane multilayering in renal allograft biopsies of patients with de novo donor-specific antibodies","volume":"100","author":"de Kort","year":"2016","journal-title":"Transplantation."},{"issue":"8","key":"10.1111\/ajt.14504_bib3","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1097\/TP.0b013e31825d1587","article-title":"The treatment of acute antibody-mediated rejection in kidney transplant recipients-a systematic review","volume":"94","author":"Roberts","year":"2012","journal-title":"Transplantation."},{"issue":"2","key":"10.1111\/ajt.14504_bib4","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1097\/TP.0000000000000958","article-title":"One-year results of the effects of rituximab on acute antibody-mediated rejection in renal transplantation: RITUX ERAH, a multicenter double-blind randomized placebo-controlled trial","volume":"100","author":"Sautenet","year":"2016","journal-title":"Transplantation."},{"key":"10.1111\/ajt.14504_bib5","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1111\/ajt.13721","article-title":"Therapeutics for ABMR: a slippery slope into confusion","volume":"16","author":"Montgomery","year":"2016","journal-title":"Am J Transplant."},{"issue":"2","key":"10.1111\/ajt.14504_bib6","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1111\/j.1600-6143.2011.03840.x","article-title":"Understanding the causes of kidney transplant failure: the dominant role of antibody-mediated rejection and nonadherence","volume":"12","author":"Sellar\u00e9s","year":"2011","journal-title":"Am J Transplant."},{"issue":"11","key":"10.1111\/ajt.14504_bib7","doi-asserted-by":"crossref","first-page":"2597","DOI":"10.1111\/j.1600-6143.2009.02798.x","article-title":"Transplant outcomes and economic costs associated with patient noncompliance to immunosuppression","volume":"9","author":"Pinsky","year":"2009","journal-title":"Am J Transplant."},{"issue":"1","key":"10.1111\/ajt.14504_bib8","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1097\/TP.0000000000000869","article-title":"The influence of immunosuppressive agents on the risk of de novo donor-specific HLA antibody production in solid organ transplant recipients","volume":"100","author":"O\u02bcLeary","year":"2016","journal-title":"Transplantation."},{"issue":"S1","key":"10.1111\/ajt.14504_bib9","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/ajt.12579","article-title":"OPTN\/SRTR 2012 annual data report: kidney","volume":"14","author":"Matas","year":"2014","journal-title":"Am J Transplant."},{"issue":"2","key":"10.1111\/ajt.14504_bib10","doi-asserted-by":"crossref","first-page":"481","DOI":"10.2215\/CJN.04800908","article-title":"Calcineurin inhibitor nephrotoxicity","volume":"4","author":"Naesens","year":"2009","journal-title":"Clin J Am Soc Nephrol."},{"issue":"25","key":"10.1111\/ajt.14504_bib11","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1056\/NEJMoa067411","article-title":"Reduced exposure to calcineurin inhibitors in renal transplantation","volume":"357","author":"Ekberg","year":"2007","journal-title":"N Engl J Med."},{"issue":"9","key":"10.1111\/ajt.14504_bib12","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1111\/ajt.12795","article-title":"A systematic review of conversion from calcineurin inhibitor to mammalian target of rapamycin inhibitors for maintenance immunosuppression in kidney transplant recipients","volume":"14","author":"Lim","year":"2014","journal-title":"Am J Transplant."},{"issue":"7","key":"10.1111\/ajt.14504_bib13","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1111\/ajt.13710","article-title":"Calcineurin inhibitor minimization, conversion, withdrawal, and avoidance strategies in renal transplantation: a systematic review and meta-analysis","volume":"16","author":"Sawinski","year":"2016","journal-title":"Am J Transplant."},{"issue":"6","key":"10.1111\/ajt.14504_bib14","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1097\/MNH.0000000000000170","article-title":"The perils of immunosuppression minimization: lessons from protocol biopsies of renal allografts","volume":"24","author":"Rush","year":"2015","journal-title":"Curr Opin Nephrol Hypertens."},{"issue":"8","key":"10.1111\/ajt.14504_bib15","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1111\/tri.12570","article-title":"Immunological risks of minimization strategies","volume":"28","author":"Snanoudj","year":"2015","journal-title":"Transpl Int."},{"issue":"2","key":"10.1111\/ajt.14504_bib16","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s40262-013-0120-3","article-title":"The role of pharmacogenetics in the disposition of and response to tacrolimus in solid organ transplantation","volume":"53","author":"Hesselink","year":"2013","journal-title":"Clin Pharmacokinet."},{"key":"10.1111\/ajt.14504_bib17","doi-asserted-by":"crossref","first-page":"623","DOI":"10.2165\/00003088-200443100-00001","article-title":"Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation","volume":"43","author":"Staatz","year":"2004","journal-title":"Clin Pharmacokinet."},{"issue":"11","key":"10.1111\/ajt.14504_bib18","doi-asserted-by":"crossref","first-page":"813","DOI":"10.2165\/00003088-200241110-00003","article-title":"Mechanisms of clinically relevant drug interactions associated with tacrolimus","volume":"41","author":"Christians","year":"2002","journal-title":"Clin Pharmacokinet."},{"issue":"6","key":"10.1111\/ajt.14504_bib19","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1038\/ki.2013.465","article-title":"Time-dependent variability in tacrolimus trough blood levels is a risk factor for late kidney transplant failure","volume":"85","author":"Sapir-Pichhadze","year":"2014","journal-title":"Kidney Int."},{"key":"10.1111\/ajt.14504_bib20","doi-asserted-by":"crossref","first-page":"2479","DOI":"10.1097\/TP.0000000000001040","article-title":"Within-patient variability in tacrolimus blood levels predicts kidney graft loss and donor-specific antibody development","volume":"100","author":"Rodrigo","year":"2015","journal-title":"Transplantation."},{"issue":"6","key":"10.1111\/ajt.14504_bib21","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1016\/j.transproceed.2016.02.081","article-title":"Higher variability of tacrolimus trough level increases risk of acute rejection in kidney transplant recipients","volume":"48","author":"Huang","year":"2016","journal-title":"Transplant Proc."},{"key":"10.1111\/ajt.14504_bib22","doi-asserted-by":"crossref","first-page":"2954","DOI":"10.1111\/ajt.13803","article-title":"High intrapatient variability of tacrolimus concentrations predicts accelerated progression of chronic histologic lesions in renal recipients","volume":"16","author":"Vanhove","year":"2016","journal-title":"Am J Transplant."},{"key":"10.1111\/ajt.14504_bib23","doi-asserted-by":"crossref","unstructured":"Wallemacq P, Armstrong VW, Brunet M, et al. Opportunities to optimize tacrolimus therapy in solid organ transplantation: report of the European consensus conference. 2009. pp. 139-152.","DOI":"10.1097\/FTD.0b013e318198d092"},{"issue":"1","key":"10.1111\/ajt.14504_bib24","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.thromres.2011.07.004","article-title":"Variability of INR and its relationship with mortality, stroke, bleeding and hospitalisations in patients with atrial fibrillation","volume":"129","author":"Lind","year":"2012","journal-title":"Thromb Res."},{"issue":"1","key":"10.1111\/ajt.14504_bib25","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1586\/14779072.6.1.57","article-title":"Outpatient management of oral vitamin K antagonist therapy: defining and measuring high-quality management","volume":"6","author":"Phillips","year":"2014","journal-title":"Expert Rev Cardiovasc Ther."},{"issue":"1","key":"10.1111\/ajt.14504_bib26","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s11239-007-0106-9","article-title":"Determinants and measures of quality in oral anticoagulation therapy","volume":"25","author":"Kaatz","year":"2007","journal-title":"J Thromb Thrombolysis."},{"issue":"3","key":"10.1111\/ajt.14504_bib27","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1055\/s-0038-1651587","article-title":"A method to determine the optimal intensity of oral anticoagulant therapy","volume":"69","author":"Rosendaal","year":"1993","journal-title":"Thromb Haemost."},{"key":"10.1111\/ajt.14504_bib28","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1111\/ajt.12590","article-title":"Banff 2013 meeting report: inclusion of c4d-negative antibody-mediated rejection and antibody-associated arterial lesions","volume":"14","author":"Haas","year":"2014","journal-title":"Am J Transplant."},{"key":"10.1111\/ajt.14504_bib29","first-page":"1","article-title":"Effect of immunosuppressive drugs on humoral allosensitization after kidney transplant","volume":"12","author":"Thaunat","year":"2016","journal-title":"J Am Soc Nephrol."},{"issue":"12","key":"10.1111\/ajt.14504_bib30","doi-asserted-by":"crossref","first-page":"3114","DOI":"10.1681\/ASN.2014121234","article-title":"Adverse outcomes of tacrolimus withdrawal in immune-quiescent kidney transplant recipients","volume":"26","author":"Hricik","year":"2015","journal-title":"J Am Soc Nephrol."},{"issue":"5","key":"10.1111\/ajt.14504_bib31","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1111\/ajt.14109","article-title":"Reduction of extended-release tacrolimus dose in low-immunological-risk kidney transplant recipients increases risk of rejection and appearance of donor-specific antibodies: a randomized study","volume":"17","author":"Gatault","year":"2017","journal-title":"Am J Transplant."},{"issue":"2","key":"10.1111\/ajt.14504_bib32","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1111\/tri.12699","article-title":"Lower tacrolimus trough levels are associated with subsequently higher acute rejection risk during the first 12 months after kidney transplantation","volume":"29","author":"Gaynor","year":"2015","journal-title":"Transpl Int."},{"issue":"10","key":"10.1111\/ajt.14504_bib33","doi-asserted-by":"crossref","first-page":"2954","DOI":"10.1111\/ajt.13803","article-title":"High intrapatient variability of tacrolimus concentrations predicts accelerated progression of chronic histologic lesions in renal recipients","volume":"16","author":"Vanhove","year":"2016","journal-title":"Am J Transplant."},{"issue":"1","key":"10.1111\/ajt.14504_bib34","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.jelectrocard.2012.08.011","article-title":"Quality of anticoagulation with warfarin in patients with nonvalvular atrial fibrillation in the community setting","volume":"46","author":"Han","year":"2013","journal-title":"J Electrocardiol."},{"issue":"1","key":"10.1111\/ajt.14504_bib35","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.ahj.2015.03.017","article-title":"Patients\u2019 time in therapeutic range on warfarin among US patients with atrial fibrillation: results from ORBIT-AF registry","volume":"170","author":"Pokorney","year":"2015","journal-title":"Am Heart J."},{"key":"10.1111\/ajt.14504_bib36","first-page":"1","article-title":"Effect of study setting on anticoagulation control","volume":"13","author":"van Walraven","year":"2015","journal-title":"Am College Chest Physicians."},{"issue":"10","key":"10.1111\/ajt.14504_bib37","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"N Engl J Med."}],"container-title":["American Journal of Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fajt.14504","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1600613522094977?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1600613522094977?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/ajt.14504\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T05:19:19Z","timestamp":1761628759000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1600613522094977"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4]]},"references-count":37,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,4]]}},"alternative-id":["S1600613522094977"],"URL":"https:\/\/doi.org\/10.1111\/ajt.14504","relation":{},"ISSN":["1600-6135"],"issn-type":[{"value":"1600-6135","type":"print"}],"subject":[],"published":{"date-parts":[[2018,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lower tacrolimus exposure and time in therapeutic range increase the risk of de novo donor-specific antibodies in the first year of kidney transplantation","name":"articletitle","label":"Article Title"},{"value":"American Journal of Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1111\/ajt.14504","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2018 American Society of Transplantation & American Society of Transplant Surgeons. Published by Elsevier Inc. All rights reserved. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}